Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Theriva Biologics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 0.22 · gapped above the open, never looked back. High/low 0.23 at 10:00 am ET, 0.22 at 3:45 pm ET.
Theriva Biologics, Inc. has 7 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Theriva Biologics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On March 4, 2016, VCN entered into a License Agreement (the "IDIBELL/ICO License Agreement") with IDIBELL and the ICO, for the exclusive license of the right to use a family of patents whose priority application is European patent application EP 14 38 2162.7 titled "Adenovirus comprising an albumin-binding moiety".”
FILING10-K0001104659-26-026767cik 0000894158
“In February 2026, we entered into a license agreement (the "Rasayana License Agreement") with Rasayana Therapeutics, Inc. ("Rasayana"), pursuant to which we granted Rasayana an exclusive worldwide license with the right to grant sublicenses to research, develop, manufacture and commercialize any Product”
FILING10-K0001104659-26-026767cik 0000894158
“In February 2019, VCN entered into a Clinical Trial Agreement with Catalan Institute of Oncology (ICO) (Spain) to conduct an investigator sponsored Phase 1 clinical study to evaluate the safety, tolerability and RP2D of a single intravenous injection of VCN-01 combined with durvalumab in two administration regimens”
FILING10-K0001104659-26-026767cik 0000894158
“In the second quarter of 2021, VCN entered into a Clinical Trial Agreement with the University of Leeds (UK) to sponsor a proof-of-concept Phase 1 clinical study to evaluate whether intravenously administered VCN-01 can cross the blood-brain barrier and infect the target brain tumor.”
FILING10-K0001104659-26-026767cik 0000894158
“VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.”
FILING10-K0001104659-26-026767cik 0000894158
“VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.”
FILING10-K0001104659-26-026767cik 0000894158
“VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.”
FILING10-K0001104659-26-026767cik 0000894158
“VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.”
FILING10-K0001104659-26-026767cik 0000894158
Watchlist prices, news filtered to it, and its next report on your desk.
TOVX (Theriva Biologics, Inc.) has 7 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TMO −0.14%, in healthcare.